NCT01344447View on ClinicalTrials.gov

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

PHASE3CompletedINTERVENTIONAL
Enrollment

479

Participants

Timeline

Start Date

May 12, 2011

Primary Completion Date

May 28, 2014

Study Completion Date

May 28, 2014

Conditions
Carotid Stenosis
Interventions
DRUG

Gadobutrol (Gadovist, BAY86-4875)

A single bolus injection of approx. 0.1mmol/kg

Trial Locations (56)

1090

Vienna

2305

New Lambton Heights

3052

Parkville

3168

Clayton

6020

Innsbruck

9007

Sankt Gallen

10467

The Bronx

11100

Aosta

13385

Marseille

14642

Rochester

19104

Philadelphia

21201

Baltimore

25240

Erzurum

29609

Brest

30174

Venezia

31406

Savannah

32209

Jacksonville

34093

Istanbul

38104

Memphis

39216

Jackson

40202

Louisville

44023

Ferrara

48145

Münster

53792

Madison

54100

Massa-Carrara

61469

Donggu

62500

Brno

69677

Bron

75877

Paris

75908

Paris

76133

Karlsruhe

85724

Tucson

91054

Erlangen

95123

Catania

98195

Seattle

200032

Shanghai

200433

Shanghai

865156

Augsburg

02114

Boston

48109-0330

Ann Arbor

02903

Providence

B1846DWA

Adrogué

C1115AAB

Buenos Aires

C1425BEE

Buenos Aires

07740

Jena

00168

Rome

85-094

Bydgoszcz

90-153

Lodz

02-097

Warsaw

50-556

Wroclaw

03722

Seoul

05505

Seoul

06351

Seoul

581 85

Linköping

751 85

Uppsala

07059

Antalya

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01344447 - Gadobutrol Enhanced MRA of the Supra-aortic Vessels | Biotech Hunter | Biotech Hunter